`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Trials <Trials@USPTO.GOV>
`Thursday, July 06, 2017 1:13 PM
`Dorothy Whelan; Trials
`IPR13351-0008IP1; IPR13351-0008IP2; IPR13351-0008IP3; IPR13351-0008IP4;
`IPR13351-0008IP5; IPR13351-0008IP6; Rosato, Michael; Parmelee, Steve; Mills, Jad;
`Devine, Wendy; GSpeier@carlsoncaspers.com; 'MSchuman@carlsoncaspers.com';
`mdzwonczyk@sughrue.com; 'tribar@sughrue.com'; 'Azy S. Kokabi
`(akokabi@sughrue.com)' (akokabi@sughrue.com); Michael Kane; Jonathan Singer;
`Susan Morrison; Tasha Francis
`RE: IPR2016-01127; IPR2016-01128; IPR2016-01129; IPR2016-01130; IPR2016-01131;
`IPR2016-01132
`
`Counsel,
`
`We grant Patent Owner’s request to file a surreply to each of Petitioner’s replies in IPR2016-01127, IPR2016-01128,
`IPR2016-01129, IPR2016-01130, IPR2016-01131, and IPR2016-01132. Patent Owner’s surreply in each case is limited to
`15 pages and due July 14, 2017.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`
`
`From: Dorothy Whelan [mailto:whelan@fr.com]
`Sent: Monday, July 03, 2017 1:25 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; IPR13351-0008IP2 <IPR13351-0008IP2@fr.com>; IPR13351-
`0008IP3 <IPR13351-0008IP3@fr.com>; IPR13351-0008IP4 <IPR13351-0008IP4@fr.com>; IPR13351-0008IP5 <IPR13351-
`0008IP5@fr.com>; IPR13351-0008IP6 <IPR13351-0008IP6@fr.com>; mrosato@wsgr.com; Parmelee, Steve
`<sparmelee@wsgr.com>; Mills, Jad <jmills@wsgr.com>; wdevine@wsgr.com; GSpeier@carlsoncaspers.com;
`'MSchuman@carlsoncaspers.com' <mschuman@carlsoncaspers.com>; mdzwonczyk@sughrue.com;
`'tribar@sughrue.com' <tribar@sughrue.com>; 'Azy S. Kokabi (akokabi@sughrue.com)' (akokabi@sughrue.com)
`<akokabi@sughrue.com>; Michael Kane <kane@fr.com>; Jonathan Singer <singer@fr.com>; Susan Morrison
`<morrison@fr.com>; Tasha Francis <tfrancis@fr.com>
`Subject: IPR2016-01127; IPR2016-01128; IPR2016-01129; IPR2016-01130; IPR2016-01131; IPR2016-01132
`
`
`
`Dear Board:
`
`
`Patent Owner requests a teleconference for the purpose of seeking leave to file a surreply or, in the alternative, a
`motion to strike regarding Petitioner’s reply briefs and supporting papers filed on June 30, 2017. The papers include 3
`new declarations, as well as over 100 new exhibits, and introduce new arguments, thereby exceeding the proper scope
`
`1
`
`MYLAN - EXHIBIT 1135
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`
`
`of a reply. Absent a surreply, Patent Owner lacks a full and fair opportunity to respond to the new material. Petitioner’s
`replies also mischaracterize deposition testimony.
`
`
`Patent Owner is available July 5, 6, and 7 for a teleconference.
`
`
`Regards,
`Dorothy Whelan
`Counsel for Patent Owner
`
`
`***************************************************************************************************
`*************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential
`and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the
`intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`***************************************************************************************************
`*************************
`
`2
`
`